title: 177Lu-Dotatate for midgut neuroendocrine tumours.
authors.forename: Talha Khan
authors.initials: TK
authors.lastname: Burki
mesh_terms: D017326:Clinical Trials, Phase III as Topic; D018450:Disease Progression; D018572:Disease-Free Survival; D006801:Humans; D007262:Infusions, Intravenous; D018358:Neuroendocrine Tumors / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D015282:Octreotide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D009942:Organometallic Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D019275:Radiopharmaceuticals / Q000008:administration & dosage* / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D009942:Organometallic Compounds; D019275:Radiopharmaceuticals; C447941:lutetium Lu 177 dotatate; D015282:Octreotide